SCHEMBL12349463

SCHEMBL12349463

CCc1ccc2sc3c(-c4ccc(-c5nc6ccccc6n5-c5ccccc5)cc4)cc(CC)cc3c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.44
ESR2 Q92731 3/20 0.44
SIRT2 Q8IXJ6 2/20 0.41
SIRT1 Q96EB6 2/20 0.41
GRIA1 P42261 1/20 0.41
CACNG8 Q8WXS5 1/20 0.41
CACNG2 Q9Y698 1/20 0.41
PTGER4 P35408 1/20 0.39
HTT P42858 2/20 0.38
MAPK1 P28482 1/20 0.38
RECQL P46063 1/20 0.37
MAPT P10636 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
ALDH1A1 P00352 5/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12349122 0.85 ESR1 (0.44) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL889699 0.85 SMN1; SMN2 (0.44) MAPK1MAPTALDH1A1PIM1PIM2
SCHEMBL12567923 0.84 ESR1 (0.47) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL1996628 0.84 ESR1 (0.47) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL12349126 0.83 ESR1 (0.42) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL12349171 0.83 ESR2 (0.46) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL12567922 0.82 ESR1 (0.41) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL12349472 0.82 ESR1 (0.41) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL12349167 0.81 ESR1 (0.42) ESR1ESR2SIRT2SIRT1GRIA1
SCHEMBL12567940 0.81 ESR1 (0.40) ESR1ESR2SIRT2SIRT1GRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2662369-B1 Benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LAB (JP) 2015-09-23 EP disclosed
EP-2354135-B1 Benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LAB (JP) 2013-09-18 EP disclosed
US-8354542-B2 Heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-01-15 US disclosed
US-8354542-B2 Heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-01-15 US disclosed
EP-2354135-A1 benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-08-10 EP disclosed
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-06-23 US disclosed
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device CCNE2, CCNE1, CCNT1 ESR1 32/4885ESR2 216/4885SIRT2 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.